NASDAQ:GLTO
Galecto, Inc. Stock News
$0.621
-0.0089 (-1.41%)
At Close: May 17, 2024
Galecto to Present at Upcoming Investor Conferences
08:00am, Tuesday, 26'th Oct 2021
BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
08:30am, Wednesday, 15'th Sep 2021
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
08:00am, Monday, 13'th Sep 2021
Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications Galecto now has three ongoing Phase 2 clinical trials with three different dr
Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)
08:00am, Wednesday, 18'th Aug 2021
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of
Galecto Reports Second Quarter Operating and Financial Results
08:30am, Thursday, 05'th Aug 2021
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced i
BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company focused on the development of novel treatments f
GLTO Stock Price: 60% Increase Explanation
10:18pm, Thursday, 10'th Jun 2021
The stock price of Galecto Inc (NASDAQ: GLTO) increased by 60% today. This is why it happened.
Galecto Reports First Quarter Financial Results and Provides a Corporate Update
08:30am, Tuesday, 04'th May 2021
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it
Galecto (GLTO) Enters Oversold Territory
07:52am, Monday, 19'th Apr 2021
Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
08:30am, Monday, 29'th Mar 2021
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced
Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time
Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.
Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB Galecto expect
Galecto to Present at Upcoming Investor Conferences
08:00am, Tuesday, 09'th Feb 2021
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye,
Galecto Appoints Anne Prener to its Board of Directors
08:00am, Friday, 08'th Jan 2021
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t
